There is different levels of evidence(e.g. Preclinical, Clinical Trials, Case Reports, FDA-approved, etc.) that a specific mutation
is considered druggable and is associated with the listed cancer types and known drug responses and effects.
There is different levels of evidence(e.g. Preclinical, Clinical Trials, Case Reports, FDA-approved, etc.) that tumors harboring a specific mutation
respond to certain drugs.
A specific mutation is identified in the literature as resistance mutation,
including mutations conferring acquired resistance (after treatment) and intrinsic resistance (before treatment).